iECURE
PrivateLast Round
Series A
Extension
Nov 30, 2022
Total Funding Raised
$115M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
iECURE operates in Healthcare & Life Sciences and is based in Blue Bell, Pennsylvania. Its latest recorded funding round was a Series A Extension round in November 2022.
iECURE is a biotechnology company developing genome editing therapies for rare, life-threatening genetic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
iECURE Comparables
Compare iECURE with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Genespire | 79% | |
| Precision BioSciences | 74% | |
| Vivet Therapeutics | 74% |
For institutional investors. Book with your work email.
iECURE Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Nov 30, 2022 | ||||
| Series A | Sep 9, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
iECURE Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| LYFE Capital | Series A Extension |
| OrbiMed | Series A Extension, Series A |
| Versant Ventures | Series A Extension, Series A |
| Novo Holdings | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 81% MoM, from 2.8K to 5.1K.
- Jul 26, 2026
Monthly visitors increased 53% MoM, reaching 2.8K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventAug 19, 2026
iECURE, Inc. plans to attend SSIEM Annual Symposium in Finland from Aug 25-28 '26, presenting clinical data from the ongoing OTC-HOPE trial and exhibiting at Booth B16.
For institutional investors. Book with your work email.
iECURE Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about iECURE's valuation, stock price, and market status.
Is iECURE a public or private company?
iECURE is a private company.
What is the current stock price of iECURE?
iECURE is a private company, so its shares have no public market price. Caplight tracks iECURE's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is iECURE worth (valuation)?
Valuation information for iECURE is not publicly available.
Can I buy iECURE stock?
iECURE shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was iECURE's last funding round?
iECURE's most recent funding round was Series A Extension on November 30, 2022.
Who are the main investors in iECURE?
Key investors in iECURE include LYFE Capital, OrbiMed, Versant Ventures, Novo Holdings.
Will iECURE IPO soon?
No public IPO plans have been announced for iECURE.
How can I track iECURE secondary market activity?
Caplight tracks bids, offers, and trades in iECURE's shares on secondary markets.